Equities

Zymeworks Inc

Zymeworks Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)16.63
  • Today's Change-0.14 / -0.83%
  • Shares traded678.74k
  • 1 Year change+134.23%
  • Beta1.1653
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy4
Outperform1
Hold3
Sell0
Strong Sell0

Share price forecast in USD

The 8 analysts offering 12 month price targets for Zymeworks Inc have a median target of 16.00, with a high estimate of 28.00 and a low estimate of 12.00. The median estimate represents a -3.79% decrease from the last price of 16.63.
High68.4%28.00
Med-3.8%16.00
Low-27.8%12.00

Earnings history & estimates in USD

On Oct 31, 2024, Zymeworks Inc reported 3rd quarter 2024 losses of -0.39 per share. This result was in line with the consensus of the 7 analysts following the company and exceeded last year's 3rd quarter results by 4.88%.
The next earnings announcement is expected on Mar 04, 2025.
Average growth rate-13.76%
Zymeworks Inc reported annual 2023 losses of -1.72 per share on Mar 06, 2024.
Average growth rate-4.14%
More ▼

Revenue history & estimates in USD

Zymeworks Inc. had 3rd quarter 2024 revenues of 16.00m. This bettered the 15.30m consensus of the 7 analysts covering the company. This was 55.03% below the prior year's 3rd quarter results.
Average growth rate+9.20%
Zymeworks Inc. had revenues for the full year 2023 of 76.01m. This was 81.57% below the prior year's results.
Average growth rate+341.20%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.